Abstract: The present application relates to novel 3-imidazolines of formula (I?) and (I) below: (I?) (I) Wherein Ar1, Ar2, Ar3, and R1 to R6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics.

Abstract: The present application relates to novel azetidinimine of formula (I). Wherein R1-R6 are as defined in claim 1. The azetidinimine of the invention are useful as antibiotics and as inhibitors of a carbapenemases. The present invention thus further relates to their use in antibiotic therapies and their methods of synthesis.

Abstract: The present application relates to novel 3-imidazolines of formula (I?) and (I) below: (I?) (I) Wherein Ar1, Ar2, Ar3, and R1 to R6 are as defined in the claims. The 3-imidazolines of the invention are useful in antibiotic therapies, in particular as inhibitors of carbapenemases. They are also useful as antibiotics themselves. The present invention also concerns a method for preparing more specifically the 3-imidazolines of formula (I). The present invention further relates to conjugates of said compounds with known antibiotics.

Abstract: The present application relates to novel azetidinimine of formula (I). Wherein R1-R6 are as defined in claim 1. The azetidinimine of the invention are useful as antibiotics and as inhibitors of a carbapenemases. The present invention thus further relates to their use in antibiotic therapies and their methods of synthesis.

Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.

Abstract: A building panel has a unitary foamed core, and a unitary cover layer of resinous polymeric material covering the core and covering a bottom edge or drip edge and an upper edge of the panel. A system for installation of adjacent panels includes the adjacent panels having vertical clip-receiving grooves slidably receiving narrow edges of a clip. The clip holds adjacent panels in coplanar abutting relationship to minimize movement while installed on a wall of a building.

Abstract: Compounds having inverse agonist functional selectivity for GABAA receptors containing the ?5 subunit for use as a medicament in the treatment of cognitive impairments in subjects suffering from Down syndrome. The use of these compounds is disclosed. Pharmaceutical compositions for such treatment can comprise these compounds or suitable pharmaceutically acceptable salt thereof, a polyethoxylated castor oil and dimethyl sulfoxide (DMSO). Methods are disclosed for enhancing cognitive function, or treating or lessening the severity of cognitive impairments, in subjects suffering from Down syndrome by administering to a subject in need thereof a pharmaceutically effective amount of one or more of these compounds.

Abstract: A building panel has a unitary foamed core, and a unitary cover layer of resinous polymeric material covering the core and covering a bottom edge or drip edge and an upper edge of the panel. A system for installation of adjacent panels includes the adjacent panels having vertical clip-receiving grooves slidably receiving narrow edges of a clip. The clip holds adjacent panels in coplanar abutting relationship to minimize movement while installed on a wall of a building.

Abstract: A distributor is described for a multi-cylinder laser ignited internal combustion engine. The distributor includes a shaft rotatable by the engine and a plurality of flat reflective surfaces on the shaft. The surfaces lie in planes normal to the axis of rotation of the shaft and are axially staggered from one another along the length of the shaft. An optical transmitter directs light from a laser source to impinge at an angle sequentially on the reflective surfaces as the shaft rotates, and a plurality of optical receivers spaced from one another each receive the light reflected from a respective one of the mirror surfaces and direct the reflected light to a respective one of the engine cylinders.

Abstract: A magnetron output arrangement includes a coaxial output adapted to be coupled in an endfire configuration to a rectangular waveguide. The waveguide has a flange for mating with the magnetron output arrangement. The coaxial output includes a central conductor. The output arrangement further includes a plate located in a predetermined position with respect to the central conductor. The plane of the plate is arranged to be substantially perpendicular to the axis of the coaxial output. The plate is located a predetermined distance from the end of the central conductor, such that the coaxial output in use couples with the plate so that the output coupling is substantially the same regardless of the type of waveguide flange employed.

Abstract: A distributor is described for a multi-cylinder laser ignited internal combustion engine. The distributor includes a shaft rotatable by the engine and a plurality of flat reflective surfaces on the shaft. The surfaces lie in planes normal to the axis of rotation of the shaft and are axially staggered from one another along the length of the shaft. An optical transmitter directs light from a laser source to impinge at an angle sequentially on the reflective surfaces as the shaft rotates, and a plurality of optical receivers spaced from one another each receive the light reflected from a respective one of the mirror surfaces and direct the reflected light to a respective one of the engine cylinders.

Abstract: The invention concerns compounds of general formula (I) wherein: the group X represents a —NR4, —CH?N or —CHR5-NR4-group; the group Y represents an oxygen or sulphur atom or a NR, —CR5, —CHR5-, —CR5=CR6- or —CHR5-CHR6 group provided that when group X represents the —CH?N— or —CHR5-NR4-group, group Y represents an oxygen or a sulphur atom or a Nr, —CR5 or —CHR group; the group R represents a hydrogen atom or an alkyl, aryl or aralkyl group; the groups R1, R5 and R6, identical or different, represent each a hydrogen or halogen atom or an alkyl or alkoxy group; the group R2 represents a hydrogen atom or an alkyl group; the group R3 represents an aryl group; and the group R4 represents a hydrogen atom, an alkyl, aryl, aralkyl, alkylsulphonamide, arylsulphonamide or aralkylsulphonamide group; and their salt with a pharmaceutically acceptable acid, in the form of a racemic mixture and their optically pure isomer.

Abstract: A process and apparatus for making a shingle, together with the shingle made thereby, is provided, in which one or more thermoplastic materials are extruded or co-extruded to form an extrudate, with the extrudate being cut into a preliminary shingle shape, which is allowed to dissipate heat, and then is delivered to a compression mold, wherein the preliminary shingle shape is compression molded to substantially its final dimensions and is then discharged from the mold and allowed to cool.

Abstract: The invention concerns diamines of general formula (I), wherein: A represents a group A1 or A2 of general formula (II); B represents a group B1 or B2 of general formula (III); X represents a SO2, CH2, C?O or COO; YZ represents a group of formula CH(R25)—CH(R26) or CH(R27)?(R28), and R1 to R28, identical or different, represent independently of one another, a hydrogen or halogen atom or an alkyl, cycloalkyl, CN, NO2, hydroxy, aryl, aralkyl, alkoxy, aryloxy, amino, alkylamino, dialkylamino, cycloalkylamino, arylamino, arylalkylamino, diarylamino diarylalkylamino, trihalogenoalkyl or trihalogenoalkoxy group, provided that in the group A1, at least one of the radicals R1, R2, R3, R4 or R5 represents the hydrogen atom when the other four do not represent the hydrogen atom and in the group B1, at least one of the radicals R13, R14, R15, R16 or R17 represents the hydrogen atom when the other four do not represent the hydrogen atom, and their salts with a pharmaceutically acceptable acid, in the form of racemic mixtu

Abstract: The invention concerns compounds represented by general formula (I) wherein: Z represents a sulfur or oxygen atom; the groups R1 and R2, identical or different, represent each a alkyl group or an alkenyl group; X represents a CO, a CO2, an SO, or an SO2 and the group R represents an alkyl, aryl, alkenyl, or aralkyl group, provided that when Z represents an oxygen atom, X an SO2 and R a group (a), R1 and R2 do not both represent the methyl group. The invention also concerns methods for preparing said compounds, pharmaceutical compositions containing them and their use as promoter of &ggr;-aminobutyric acid and as medicine particularly designed for treating nervous disorders.

Abstract: The invention concerns compounds of general formula (I) wherein: Z represents a sulphur or oxygen atom, NH, N-alkyl or Nboc; group R′, identical or different, represent each a hydrogen atom, a OCH3 group or a OCH2O group; group R″ represents a hydrogen or a CH3 group; group X represents a carbonyl, sulphonyl or CO2 group; and group R represents an alkyl, aryl, alkenyl or aralkyl group. The invention also concerns the preparation of said compounds, pharmaceutical compositions containing them and their use for stimulating &ggr;-amino-butyric acid activity and as medicine for treating nervous disorders.

Abstract: The invention concerns compounds of general formula (I) wherein: 1

Abstract: The invention relates to novel .beta.-carboline-derived compounds which are benzodiazepine-receptor ligands having an inverse agonist and antagonist effect on benzodiazepines. These compounds are of the formulae: ##STR1## in which: X is O, S, ##STR2## or alternatively, ##STR3## represents the radical --N(R.sub.6)--C(=O)--CH.sub.2 --X, R.sub.1 is a hydroxyl, alkoxy or alkyl radical substituted by a hydroxyl or alkoxy radical,R.sub.2 is a hydrogen atom or an alkyl, hydroxyl, alkoxy, acyloxy or benzyloxy radical, it being possible for said radicals to be optionally substituted,R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are chosen from a hydrogen atom or an alkyl radical optionally substituted by a hydroxyl, alkoxy or alkoxycarbonylmethyl radical,as well as the corresponding tetrahydro derivatives of .beta.-carboline and the quaternary ammonium salts or derivatives of these pharmaceutically acceptable compounds.